Cancer is classically considered as a genetic and, more recently, epigenetic multistep disease. Despite seminal studies in the 1920s by Warburg showing a characteristic metabolic pattern for tumors, cancer bioenergetics has often been relegated to the backwaters of cancer biology. This review aims to provide a historical account on cancer metabolism research, and to try to integrate and systematize the metabolic strategies in which cancer cells engage to overcome selective pressures during their inception and evolution. Implications of this renovated view on some common concepts and in therapeutics are also discussed.
The origins of cancer metabolism research
Cancer metabolism has been experiencing a renovated interest, not only because of the growing awareness that oncogenes and tumor-suppressor genes are bioenergetic arbiters, but also because it may reveal therapeutic targets. Notably, some misconceptions regarding the initial observations and ensuing theories in cancer metabolism exist. We thus start by addressing the initial advances in this field, in order to better analyze its evolution.
The Warburg effect
Otto Warburg, who won the Nobel Prize in Physiology or Medicine in 1931 for groundbreaking work on electron-transferring enzymes, is most famous for his seminal studies on cancer energy metabolism, the milestones of which are reviewed elsewhere (Ferreira, 2010) . In those works, a specific metabolic pattern of tumors was consistently observed. After some anecdotal reports on metabolic reactions in tumor tissues, Warburg developed a highly accurate manometrical apparatus to measure oxygen and carbon dioxide partial pressures (Warburg, 1923; Warburg and Minami, 1923) . Then, he conducted experiments in tissue slices of rat sarcoma, human tumors and normal tissues, observing a remarkably consistent pattern: whereas in normal tissues production of lactate occurred almost exclusively during oxygen deprivation, it was not ablated in tumor slices by the presence of ample oxygen and surpassed that of normal tissue (Warburg et al., 1924) . This phenomenon, later termed Warburg effect or 'aerobic glycolysis' (Racker and Spector, 1981) , prompted him to put forward a first hypothesis on the origin of tumors: when tissues are subjected to chronic oxygen deficiency, damage to respiration occurs and only cells that succeed to achieve the high glycolytic activity characteristic of embryonic cells survive to give rise to a tumor (Warburg et al., 1924) . Later studies by him (Warburg et al., 1927) and others Cori, 1925a, 1925b) confirmed that solid tumors presented higher glucose uptake and lactate extrusion than healthy tissues in vivo. During the following years, it became clear that aerobic glycolysis was not restricted to tumors (Warburg, 1929) , leading Warburg to include in his hypothesis that, in tumors, a damage to respiration was irreversible and transmitted at each cell doubling (Warburg, 1930) . It was not until the 1950s that the shift from respiration to fermentation in fully aerated conditions could be confirmed in pure cancer cell cultures (Warburg and Hiepler, 1952) . This, together with a breakthrough report that rat myocardial cells formed malignant tumors upon exposure to intermittent hypoxia (Goldblatt and Cameron, 1953) , led Warburg to propose that irreversible damage of respiration was at the origin of cancer cells: the 'morphological inferiority' of energy acquired through fermentation converted differentiated somatic cells into 'undifferentiated cells that grow wildly-the cancer cells' (Warburg, 1956a) .
Bioenergetic etiology of cancer under fire All these innovative findings and bold assertions elicited several criticisms casting doubt on the methods used and results' analysis (Ferreira, 2010 ). An illustrative example is a debate sparked by Sidney Weinhouse on Warburg's original hypothesis (Burk and Schade, 1956; Warburg, 1956b; Weinhouse, 1956 ). Weinhouse considered Warburg's claims that oxidative phosphorylation (OXPHOS) was altered in cancer cells as unfounded, based not only on extensive data showing that oxygen consumption was not diminished in cancer cells, but also on experiments, performed in his (Wenner and Weinhouse, 1953) and other (Boyland and Boyland, 1935) laboratories, showing that OXPHOS could be enhanced in tumor tissues.
Importantly, advances in cancer metabolism were highly interwoven with those of bioenergetics in general. When the Warburg effect was first described, very little was known about the cross-signaling between respiration and fermentation; the tricarboxylic acid cycle (TCAC) was first described only in the 1930s (Krebs and Johnson, 1937) . Nevertheless, Crabtree suggested already in 1929 that exacerbated glycolytic activity hampered respiration, not only in tumors but also in other mitotically active tissues. The inhibition of oxygen consumption by glucose in proliferating cells was then named the Crabtree effect (Guppy et al., 1993) . Decades later, Weinhouse (1972) observed that tumor cells possess fetal isoforms of some glycolytic enzymes, suggesting this could be responsible for their increased glycolytic flux.
During the 1940s, Lynen suggested that competition by free phosphate for ATP synthesis coordinated glycolysis and OXPHOS fluxes (Lynen, 1942) , and much probably provided the basis for the Pasteur effect, the inhibition of lactic fermentation by oxygen (Pasteur, 1876) . Moreover, he highlighted studies showing that 2,4-dinitrophenol conspicuously increased oxygen consumption in muscle through ATP depletion (Ronzoni and Ehrenfest, 1936) . Hence, oxygen consumption could remain high if respiration was not efficiently coupling oxygen reduction to ATP generation; lactic fermentation would fill the gap even in aerobiosis. Remarkably, such theory was put forth before the chemiosmotic theory of Mitchell was published (Mitchell, 1961 ). Yet, it inspired the current idea that mitochondrial uncoupling, rather than irreversible inheritable OXPHOS defects, drives the metabolic reprogramming of the tumor (Samudio et al., 2009) .
Despite all these progresses, investigation on cancer bioenergetics became little considered by the majority of the scientific community during several decades. Why?
Oblivion and renaissance of cancer metabolism Since the observation of gross chromosomal abnormalities in several cancers (Hansemann, 1890) and the proposal that this feature could be the trigger of carcinogenesis (Boveri, 1914) , the history of experimental oncology overlaps almost perfectly with that of research on the genetic regulation of cell growth and division.
Warburg's original observations and hypotheses on cancer ontogeny (Warburg et al., 1924) remained largely unconsidered by the majority of cancer researchers. Two main classes of theories existed then: the parasitic concept, where cancer was provoked by some extrinsic factor, and the biological concept, where this pathology resulted from disturbances in cell regulatory mechanisms. By 1925, both were considered to be erroneous: the first because cancer affected a wide range of species with similar features, but was not transmissible between them. The second because consistent differences between normal and cancer cells remained to be observed (Cramer, 1926) . The latter observation ignored the cytogenetic and metabolic patterns observed by Hansemann and Warburg, respectively, in tumor tissues, perhaps because of the scarcity of available knowledge. The correct number of human chromosomes was determined only in the 1950s (Tijo and Levan, 1956) ; normal cells were believed to be immortal (Carrel and Ebeling, 1921) ; and cyclins, proteins responsible for controlling cell-cycle progression, were discovered only in 1982s (Evans et al., 1983) .
During the 1960s, it was first suggested that every cancer resulted from expression of conserved viral transforming genes, named oncogenes at that time (Huebner and Todaro, 1969) . Then the first oncogene was finally described: SRC (for 'sarcoma'), a gene responsible for tumor induction upon integration into the host genome (Stehelin et al., 1976) .
This framework could not account for all cancer cases. Based on his observations of retinoblastoma, an early childhood eye cancer, Knudson established that this tumor always needed two mutations. Therefore, it was a recessive disease, not compatible with the dominant effect of proto-oncogene mutations (Knudson, 1971) . These mutations were later found to be on the alleles of the same gene, leading to the discovery of the first tumor-suppressor gene, RB (for 'retinoblastoma') (Lee et al., 1987) .
These discoveries regarding the genetic entities responsible for neoplastic growth relegated metabolism to the backwaters of cancer biology. The realization that proto-oncogenes and tumor-suppressor genes govern cell growth and division ultimately led to the current concept of cancer as a stepwise genetic disease caused by rounds of clonal selection of abnormally activated proto-oncogenes and/or inactivated tumor-suppressor genes (Fearon and Vogelstein, 1990) . Metabolism has been recently considered as an important cancer property (Hanahan and Weinberg, 2011) , but the relevance of the Warburg effect, and whether it is a cause or a consequence of carcinogenesis, are still contentious topics (Ferreira, 2010) .
The new interest in cancer metabolism already has an impact in the clinic, both in diagnosis (Pauwels et al., 2000) and therapy (Tennant et al., 2010) . In the next sections, we review cancer metabolic reprogramming, emphasizing its dynamic intertwining with key events occurring during malignant transformation.
Early steps in carcinogenesis and metabolism
The pathway to immortality of the cancer cell Mutations in tumor-suppressor genes and oncogenes are central to early immortalization of neoplasias. With regard to the first, p53 is a tumor-suppressor protein that overhauls genome integrity by triggering cell-cycle arrest or apoptosis in response to DNA damage (Levine, 1997) . More than half of human cancer types present mutations in the TP53 gene (Hollstein et al., 1991) , probably because its normal activity would hamper the accumulation of genetic lesions needed for malignant progression (Campbell et al., 2010) . Albeit TP53 knockout suffices to immortalize mouse cells (Carnero et al., 2000) , no similar outcome has been observed in human cells unless they constitutively express telomerase, possibly owing to the shortness of human telomeres, which limits their lifespan (Hahn and Weinberg, 2002) . Nonetheless, it is possible to immortalize primary human prostate epithelial cells by ectopic expression of c-MYC , an oncogene overexpressed in approximately 30% of human cancers (Dang et al., 2008) . MYC induces telomerase expression , and activates the self-renewal core circuitry in both normal human primary epithelial cells and tumor cells in vivo (Wong et al., 2008) .
The metabolic pattern of cancer cells
The genetic circuitry rewiring occurring during carcinogenesis is accompanied by a bioenergetic reprogramming that bestows cancer cells properties necessary for successful tumor formation and metastasis. Several recent reviews have considered particular aspects of the subject (Semenza, 2010; Berardi and Fantin, 2011; Brahimi-Horn et al., 2011; Cairns et al., 2011) . The major bioenergetic pathways in cancer cells are summarized in Figure 1 .
Eukaryotic cells have developed mechanisms to adjust metabolism to their energetic status, as defined by the relative intracellular concentrations of AMP, ADP and ATP, the adenylate energy charge (Atkinson, 1968) . AMP-activated kinase (AMPK) is a heterotrimeric protein exquisitely sensitive to variations in AMP and, as recently found, ADP levels (Oakhill et al., 2011) . Upon nutrient deprivation, AMPK becomes activated and downregulates ATP-consuming processes and upregulates the ATP-generating ones. Inhibition of HMG-CoA reductase and acetyl-CoA carboxylase by AMPK represses cholesterol and fatty acid biosynthesis, respectively (Kahn et al., 2005) . AMPK also phosphorylates TSC2 and Raptor, abrogating the mammalian target of rapamycin (mTOR)-signaling pathway, which is essential for protein synthesis through activation of amino-acid uptake, tRNA charging and translation initiation (Jones, 2009) .
Cancer cells are characterized by increased glycolysis and lactate output rates. What is so special about glycolysis? Glucose levels in blood are exquisitely maintained at approximately 5 mM under physiological conditions (Rodgers et al., 2005) . Remarkably, this substrate represents the major energy (Guppy et al., 1993) and carbon source of proliferating cells; glucose deprivation can induce cellcycle arrest (Holley and Kiernan, 1974) and death (Ahmad et al., 2005) . Thus, variations in glucose availability/utilization arising within specific cell niches generate clonal selection pressures. Conspicuous rates of glucose uptake in tumor cells result from the overexpression of glucose facilitative transporters, GLUTs (Pauwels et al., 2000) . Augmented GLUT1 expression and translocation may arise through tumor-suppressor activity knockdown (Schwartzenberg-Bar-Yoseph et al., 2004) and/or oncogene over-activity (Flier et al., 1987; Osthus et al., 2000) . This glucose torrent is canalized Figure 1 An overview of mammalian cell energy metabolism. The main carbon sources of mammalian cells are glucose and glutamine. Glucose is immediately phosphorylated to glucose-6-phosphate after entering cells. This metabolite can then be used for glycogen synthesis, ribose and NADPH production through the pentose phosphate pathway, or to generate pyruvate and ATP by glycolysis. In the presence of oxygen, pyruvate carbons usually enter the TCAC, which occurs in mitochondria, through formation of the intermediate acetyl-coenzyme-A (AcCoA). TCAC reactions drive the formation of NADH and FADH 2 , which then cede their electrons to the ETC to generate ATP. Pyruvate can also be reduced to lactate. On the other hand, glutamine is transported into the cell and then to the mitochondria, where glutaminase converts it to glutamate; the latter is then converted to a-ketoglutarate, a TCAC intermediate. The relative flux increases refer to cancer cells in general in comparison with normal cells (see also Cairns et al., 2011). into glycolysis, allowing greater ATP production rates (Guppy et al., 1993) . Furthermore, part of glucose-6-phosphate is shunted to the pentose phosphate pathway, generating ribose and NADPH, which sustain increased nucleic acid and fatty acid biosynthetic demands (Ramos-Montoya et al., 2006) . Accordingly, augmented glucose fluxes avoid oxidative stress and delay senescence in primary cell cultures (Kondoh et al., 2005) . Increased ribose phosphate generation from phosphoglycerate mutase uncouples glycolysis from ATP formation in proliferating cells (Vander Heiden et al., 2010) . Pyruvate not oxidized through the Krebs cycle generates citrate through pyruvate carboxylase and which is used by ATP citrate lyase to generate acetylCoA for lipogenesis . Paradoxically, the increased usage of glycolysis may provide cancer cells with a growth advantage, as they starve their normal counterparts in the premalignant niche. Besides, several lines of evidence suggest that squelching mitochondrial bioenergetic activity promotes tumor growth. Studies in mice, whose liver cells were devoid of frataxin, a mitochondrial protein that upregulates OXPHOS-mediated ATP synthesis, have shown a strong correlation between mitochondrial impairment and tumor promotion (Thierbach et al., 2005) . Later in vitro studies found that overexpression of frataxin in colon cancer cell lines enhanced mitochondrial respiration and concomitantly diminished their tumorigenicity (Schulz et al., 2006) . Similarly, genetic manipulation of the levels of PGC1a, a transcription factor whose activity fosters mitochondrial biogenesis, OXPHOS and fatty acid oxidation, revealed that knockout of PGC1a provokes intestinal tumor susceptibility whereas its overexpression hampers colorectal carcinogenesis (D'Errico et al., 2011). Other observations suggest a lower mitochondrial and a higher glycolytic activity: human tumor tissues show lower levels of H þ -ATP synthase, the molecular motor that couples the mitochondrial proton gradient to ATP synthesis, and higher levels of glycolytic enzymes when compared with normal tissue biopsies (Isidoro et al., 2004) . In strongly glycolytic anaplastic and papillary thyroid carcinomas, each tumor shows a specific panel of glycolytic gene overexpression (Hebrant, personal communication) .
Lactate overproduction by glycolysis is also an important part of cancer metabolic rewiring. Neoplastic cells accomplish the consumption of the surplus pyruvate generated by glycolysis, which is not fed into the TCA cycle, also by conversion into lactate by lactate dehydrogenase (LDH)-A (Shim et al., 1997) and by fueling it into lipid biosynthesis . Removal of this excess of pyruvate molecules is crucial to avoid pyruvate-induced apoptosis (Thangaraju et al., 2006) . In addition, overexpression of the monocarboxylate transporter (MCT4) gene allows augmented extrusion of lactate along with protons to the extracellular milieu (Gallagher et al., 2007) . At this level, lactate has a central role in promoting disordered growth by stimulating the production of hyaluronan and the expression of its membrane receptor, CD44, enhancing cell motility and extracellular matrix looseness (Stern et al., 2002) . Equally important is the H þ extrusion and the extracellular acidification brought not only by MCT4 (Gallagher et al., 2007) but also by Na þ /H þ exchangers (Reshkin et al., 2000) and other transmembrane channels whose levels are orchestrated in cancer cells (Pouyssegur et al., 2006) . This strategy maintains intracellular alkalinization, exerting a positive feedback loop on glycolysis, through activation of 6-phosphofructo-1-kinase (Erecinska et al., 1995) , whereas extracellular acidification triggers apoptosis in neighboring cells with normal p53 levels (Williams et al., 1999) .
Role of oncogenes and tumor-suppressor genes in Darwinian selection and metabolism When two cell subpopulations with different metabolic potentials arise within a growing tissue, competition selects the one with a growth advantage, which will contribute more to the final tissue composition (Johnston, 2009 ). Likewise, cancer cells thrive and undergo several rounds of clonal selection. Genetic mutations that affect their cell-cycle and apoptotic machinery, which confer them self-sustained constitutive growth and proliferation, also impact on cell bioenergetics (Figure 2) .
Along with their roles in cell-cycle control (Levine, 1997; Dang et al., 2008) , p53 and MYC also have cardinal roles in metabolic control. At normal levels, p53 induces TIGAR (Bensaad et al., 2006) , which in turn downregulates glycolytic flux through dephosphorylation of fructose-2,6-bisphosphate, an important 6-phosphofructo-1-kinase allosteric activator (Yalcin et al., 2009) . On the other hand, p53 fosters mitochondrial respiration through expression of SCO2, a positive regulator of cyclooxygenase, the oxygen-consuming complex of the electron transport chain (ETC) (Matoba et al., 2006) , presumably preventing reactive oxygen species (ROS) generation. TIGAR also increases reducing power through oxidized glutathione reduction by NADPH generated by the pentose phosphate pathway (Bensaad et al., 2006) . Consistent with this, TP53 knockout augments ROS levels (Lebedeva et al., 2009) . Thus, p53 prevents ROS accumulation and consequent DNA damage.
p53 also halts cell growth. It is activated by stresses such as DNA damage and nutrient deprivation. Through induction of the tumor suppressor PTEN, it inhibits AKT activity. AKT indirectly activates mTOR and, consequently, protein synthesis by blocking TSC2 (Feng and Levine, 2010) . Importantly, AKT participates in the genesis of some cancers (Staal, 1987) . Besides, it has recently been shown to elicit alone aerobic glycolysis in cancer cells by increasing glucose import and the levels of glycolytic enzymes (Elstrom et al., 2004 ). An additional mechanism through which AKT induces glycolysis is phosphorylation of hexokinase-II, which prompts its association with the voltage-dependent anion channel at the outer mitochondrial membrane. Remarkably, the implications of this event are threefold. First, it renders hexokinase-II less sensitive to product feedback inhibition and proteolytic degradation (Rempel et al., 1994) . Second, it brings it physically closer to OXPHOS-derived ATP, thus increasing the rate at which glucose phosphorylation can occur (Kroemer and Pouyssegur, 2008) . Finally, it prevents mitochondrial depolarization and cytochrome-c release, thus participating in the anti-apoptotic effects of AKT (Miyamoto et al., 2008) .
Noteworthy, sustained starvation activates AMPK, which in turn prompts p53 protein accumulation, leading to p53-driven cell-cycle arrest (Jones et al., 2005) and apoptosis (Okoshi et al., 2008) . Finally, p53 also functions as a sensor of the extracellular chemical environment, initiating an apoptotic cascade in response to constitutive acidosis (Williams et al., 1999) and hypoxia (Hammond and Giaccia, 2005) .
MYC activates glycolysis through transcriptional induction of various glycolytic enzymes and LDH-A (Shim et al., 1997; Kim et al., 2004) . Recent experiments using double transgenic mice expressing c-MYC in a doxycycline-dependent manner specifically in hepatocytes revealed that overexpression of a multitude of glycolysis genes in tumors was abrogated by switching off c-MYC expression . Less mentioned are the increase in mitochondrial mass and function achieved by ectopic expression of c-MYC (Li et al., 2005) , and the p53-dependent apoptosis that may follow MYC over-activity (Lowe et al., 2004) . This suggests that c-MYC overexpression and TP53 inactivation, or other alterations that phenocopy their effects, could simultaneously induce neoplastic growths and the high glycolytic fluxes uncoupled from OXPHOS observed therein (Gatenby and Gillies, 2004) .
Bioenergetics and the tumor microenvironment
When neoplastic growth becomes macroscopic, tumor cells and various types of normal host cells interact with one another, forming the tumor niche (Hanahan and Weinberg, 2011) . Then, differences in the availability of nutrients become increasingly more notable amid cancer cells (Figure 3) .
The oxygen-sensing machinery allows cells to adapt to hypoxia. Hypoxia-inducible factor (HIF)-1 is a heterodimeric transcription factor responsible for this process by increasing glycolytic flux, through upregulation of genes encoding glucose transporters, glycolytic enzymes and LDH-A, while inhibiting OXPHOS, by squelching pyruvate entry into the TCAC through PDK1-mediated inactivation of pyruvate dehydrogenase (Semenza, 2009) . Under normoxic conditions, both HIF subunits, HIF-1a and HIF-1b, are continuously synthesized, but HIF-1a is targeted for ubiquitin-dependent degradation through hydroxylation by a family of prolyl hydroxylases (Bruick and McKnight, 2001) . When the abundance of oxygen, the final electron acceptor of the mitochondrial ETC, decreases, electron leakage at complex-III generates ROS (Klimova and Chandel, Abbreviations are as they appear in the text. GLS2, glutaminase-2; LDH-A, lactic dehydrogenase; PDH, pyruvate dehydrogenase; PDK, PDH kinase; MCT, lactate transporters; GLUTs, glucose transporters (-). Chemical transformation or transport, ... c activation, ---c induction, ---I repression. In brief, p53 fosters OXPHOS in normal cells byrepressing glycolysis by TIGAR and PTEN induction, and by activating SCO2. In cancer cells, the shift to lactic fermentation is achieved not only through p53 function loss and concomitant AKT unchecked activity, but also by MYC activity, which activates glucose transport, glycolytic enzymes and lactate extrusion. MYC also favors mitochondrial biogenesis, but this is counteracted by constitutive activity of HIF-1, which can be brought not only by hypoxia but also through TP53 knockout or c-MYC overexpression (Berardi and Fantin, 2011) . There are also effects of oncogenes through phospatidyl inositol-3-kinase and HIF. HIF-1, besides favoring lactic fermentation as MYC, blocks pyruvate entry into TCAC. Mitochondrial fraction is then maintained by glutamine, whose transport and metabolism are upregulated by MYC. Angiogenesis owing to VEGF-A action allows tumors to obtain nutrients to sustain their metabolism during their uncontrolled growth (Semenza, 2010; Cairns et al., 2011). 2008). Both ROS and hypoxia itself inhibit prolyl hydroxylase activity, rescuing HIF-1 (Klimova and Chandel, 2008) . Strikingly, TP53 knockout (Ravi et al., 2000) and c-MYC overexpression (Shim et al., 1997) also increase HIF-1 activity. Although HIF-1a is overexpressed in a wide array of human cancers (Semenza, 2003) and fosters their aggressiveness (Akakura et al., 2001) , it induces cell-cycle arrest in normal cells through MYC repression (Koshiji et al., 2004) . Interestingly, c-MYC overexpression results in cooperation between MYC and HIF-1, inducing a shift from OXPHOS to lactic fermentation (Kim et al., 2007) . Recently, another link between glycolysis, MYC and HIF-1 has been unveiled. Cancer cells typically express a fetal isoenzyme of pyruvate kinase, PKM2, instead of the regular PKM1. They are both products of the same gene, PKM, that arise through alternative splicing. In tumors, MYC transcriptionally upregulates ribonucleic proteins that lead to preferential expression of PKM2 over PKM1 (David et al., 2010) . Unlike PKM1, the less active PKM2 can be inhibited by phosphotyrosine-containing proteins, allowing accumulation of phosphorylated glycolytic intermediates, which will be used for biosynthesis (Christofk et al., 2008) . Curiously, it was found that PKM transcription is activated by HIF-1 and PKM2, but not PKM1, becomes associated with HIF-1a, enhancing HIF-1 binding to its target genes (Luo et al., 2011) , thus constituting a positive feedback loop. The lower activity of PKM2 contributes to the lower use of pyruvate by mitochondria and thus to supplement the effect of the AKT oncogene (Elstrom et al., 2004) .
Short intermittent pulses of hypoxia select cells with increased reliance on glycolysis (Kroemer and Pouyssegur, 2008) . ROS generation increases during this stress situation, activating HIF-1 (Toffoli and Michiels, 2008) , which then associates with and stabilizes wild-type p53 in normal cells , inducing their apoptosis (Hammond and Giaccia, 2005) . Thus, only cells with inactivated p53 would survive, which would explain the survival of these cancer cells but not of those with intact p53. Moreover, intermittent hypoxia also provokes the degradation of the tumor suppressor PTEN, allowing constitutive AKT activity (Cai and Semenza, 2005) . Therefore, the reports used by Warburg as evidence supporting his hypothesis of a respiratory impairment as a trigger of cancer (Warburg, 1956a) , showing that cyclic oxygen deprivation could induce tumors per se (Goldblatt and Cameron, 1953) , might well have AKT as one underlying mechanism provided p53 is inactivated.
HIF-1a orchestrates several strategies that promote the adaptation of incipient tumors to metabolic stress. First, HIF cooperates with oncogenic MYC to foster OXPHOS-uncoupled glycolysis (Kim et al., 2007) . Second, it provokes E-cadherin loss in carcinoma cells (Imai et al., 2003) , summoning a cell biological program, the epithelial-mesenchymal transition (EMT), whereby a tightly concerted alteration in gene expression leads to the transformation of epithelial cells into pseudomesenchymal cells (Thiery and Sleeman, 2006) . This endows cancer cells with novel properties, such as anchorage-independent growth, and enhanced motility Figure 3 Proposed roles of cancer metabolism in the expression of cancer hallmarks (Hanahan and Weinberg, 2011) . The hallmarks concern the cancer cells themselves except apoptosis, which concerns neighboring normal cells (Semenza, 2010; Brahimi-Horn et al., 2011; Cairns et al., 2011) . The glucose uptake rates of cancer cells are much higher that those of neighboring cells, leading to apoptosis of the latter. High glycolytic fluxes allow rapid processing of glucose into lactate, which, together with protons, induces apoptosis in normal cells, blocks immune cell function and guides tissue invasion by tumors. Glutamine also arises as an important substrate for cancer cells, leading to the production of ammonia, which then activates autophagy, fostering cancer cell viability. Hypoxia existing in tumors is not only responsible for tumor radioresistance, but also supports angiogenesis and metastasis through HIF-1 activity. Abbreviations are as they appear in the text. -Chemical transformation or transport, ... c activation, ---c induction, ---I inhibition.
and resilience, established hallmarks of cancer invasion (Thiery and Sleeman, 2006; Mani et al., 2008) . Finally, it transcriptionally activates vascular endothelial growth factor (VEGF)-A (Ikeda et al., 1995) and angiopoietin-2 (Mandriota and Pepper, 1998) , initiating angiogenesis. Moreover, lactate triggers VEGF-A production, resulting in further induction of neovascularization (Milovanova et al., 2008) , which is essential for tumor growth (Folkman, 2003) . Nutrient access heterogeneity among cell subpopulations of a solid tumor arises as a consequence of these processes (Thomlinson and Gray, 1955; Guppy, 2002) .
The progressive loss of glucose as mitochondrial substrate (Semenza, 2009 ) in tumor cells is often compensated by glutamine metabolism (DeBerardinis et al., 2007) . In fact, ammonia levels in the interstitial fluid of xenografts were found to reach 5 mM, a 10-fold increase over physiological values (Eng et al., 2010) , and it has long been known that neoplastic cells overexpress glutaminase along with tumor growth and dedifferentiation (Knox et al., 1969) . Increased glutamine uptake and utilization are powered by MYC (Gao et al., 2009) . Interestingly, ammonia derived from glutamine oxidation enhances cell viability in the tumor microenvironment, acting as a diffusible activator of autophagy (Eng et al., 2010) , a process responsible for damaged protein and organelle turnover that serves as a defense against nutrient deprivation and hypoxia (Mizushima et al., 2008) .
In the interstitial medium of tumors, lactate hits concentrations as high as 15 mM, a seven-fold increase over physiological levels (Gladden, 2004) , and triple of that of glutamine (Eng et al., 2010) and glucose (Rodgers et al., 2005) . Solid tumor cells are exposed to a decreasing gradient of oxygen concentration from the irrigating vessels to the periphery. MCT1, whose product transports lactate from the medium to the cell, is expressed in the cells of the oxygenated part. This suggests that anoxic cells with high glycolytic activity use MCT4 channels to pump out lactate, which is taken up by cells with access to oxygen through MCT1. Indeed, cancer cell lines with each phenotype have been characterized in vitro (Sonveaux et al., 2008) . This strongly suggests that, within a tumor, cells closer to blood supply take up surplus lactate thus sparing glucose for the inner cells, supporting their constitutive lactic fermentation. In the outer cells, lactate oxidation might be an expedite source of energy and reducing power, as suggested by the discovery that prostate cancer cells present higher activity of a novel LDH isoform, which converts lactate to pyruvate inside mitochondria (De Bari et al., 2010) . It is not surprising that tumor cells responsible for recurrence after treatment (Li et al., 2008) and metastasis (Tubiana and Koscielny, 2008) would be the most hypoxic ones, as their sustained high glycolytic rates (Kondoh et al., 2005) and autophagic activity (Eng et al., 2010) would render them more resilient and aggressive.
In solid tumors, bioenergetic cooperation between cancer cells and neighboring normal ones may replace competition. Recent studies revealed that, whereas colorectal cancer cells present high levels of GLUT1 and LDH5, which favors the conversion of glucose and pyruvate to lactate, tumor-associated fibroblasts have low levels of GLUT1 and express LDH1, favoring the opposite reaction. Provided there is MCT activity in both cell types, this would allow a complementarity between the energy generation processes of tumors and the associated stroma (Koukourakis et al., 2006) .
Hence, the bioenergetic strategy adopted by each cell within a tumor is finely tuned by nutrient availability and the metabolic status of the neighboring cells.
Breaking barriers: cancer invasion, metastasis and cell metabolism
Destruction of tissue structure The acquisition of a fully malignant state encompasses the capacity to spread over the host organism and form secondary tumors, in a process called metastasis (Campbell et al., 2010) . For solid cancers, invasion of normal tissue is the first step of this process. Cancer cells trigger the degradation of the basement membrane and the extracellular matrix, which separates the epithelial tissue from blood vessels, through the degrading activity of metalloproteinases (Kim et al., 1998) , which are induced by HIF-1 activity (Pouyssegur et al., 2006) and activated by low pH (MartinezZaguilan et al., 1996) .
Invasion follows the disruption of the normal tissue architecture, and results from both cell multiplication and movement. There are two main mechanisms: invasion in bulk, in which the aggregated mass of cancer cells progressively pushes its way through the environment, hydrolyzing matrix proteins upfront and re-synthesizing them around, and single-cell invasion, where individual cells progress through the matrix. EMT provokes loss of connection to other cells and changes their morphology, from an epithelial-to a fibroblast-like structure (Thiery, 2002; Thiery and Sleeman, 2006; Thiery et al., 2009; Cannito et al., 2010) . This process is reversible; such cells are able to regenerate the bulk-like character of their tumors of origin after metastasis (Pinner et al., 2009; Floor et al., 2011) .
The rate of invasion of the single-cell process, in vitro and in vivo, is much faster than the progression in bulk (Alexander et al., 2008; Friedl and Gilmour, 2009 ). There are two major types of single-cell movements: through the matrix, as in bulk progression, with digestion of the matrix upfront and its re-synthesis after passage and amoeboid movement around and in between the matrix. All these modes of invasion are reversible and inducible. Several extracellular signals for EMT and their downstream transcription factors have been identified and characterized. Importantly, these switches in gene transcription and translation require hours at least to occur (Berx and van Roy, 2009 ).
There are environmental correlates to the EMT process. The switch from cytokeratin to vimentin expression takes place at the periphery and the invasive front of the tumor (Wu et al., 2009) . As in tumor growth, hypoxia induces HIF-1, as a pleiotropic master switch of the cell biological processes responsible for tumor invasion. Its activity leads to constitutive lactate production (Kim et al., 2007) , angiogenesis (Ikeda et al., 1995; Mandriota and Pepper, 1998) , metalloproteinase expression (Pouyssegur et al., 2006) and EMT induction (Imai et al., 2003) . From the point of view of the cancer cell, moving to other sites when microenvironment conditions become detrimental makes sense.
It is generally assumed that intravasation and circulation of cancer cells to new seeding places involve single cancer cells (Giampieri et al., 2009; Campbell et al., 2010; Madsen and Sahai, 2010) . Once in the blood stream, these circulating cells originating from pseudomesenchymal cells are exposed to the host immune system that may recognize them as damaged cells and consequently targets them for destruction. Besides intravasation, metastasis also requires extravasation and proliferation at the metastatic site. The few surviving cancer cells undergo cytoskeletal remodeling to extravasate and then invade the stroma of different tissues (Miles et al., 2008) where they may reverse to an epithelial morphology and reconstitute an analog of the original tumor, the metastasis.
Resistance to immune reactions: the role of metabolism Several strategies are used by malignant cells to evade immunosurveillance, as reviewed elsewhere (Stewart and Abrams, 2008) .
Besides their classical immune evasion mechanisms (for example, loss of antigen-presenting proteins), cancer cells neutralize immune cells by using their metabolism: excretion of lactate and glutamate, resulting from high activity of LDH-A (Shim et al., 1997) and glutaminase (Knox et al., 1967) , respectively, was found to affect the host immune response.
Lactate functions as a potent immunosuppressor at solid tumor borders. T lymphocytes and natural killer cells, the cytotoxic lymphocyte types responsible for triggering apoptosis of cells with defects or perceived as foreign, such as cancerous ones (Stewart and Abrams, 2008) , are highly glycolytic. Their normal functions are perturbed when their MCT channels cannot efficiently extrude lactate and protons because of an excess of these molecules in the extracellular milieu (Lardner, 2001; Fischer et al., 2007) . Accordingly, it has long been known that low pH and glucose scarcity, normal bioenergetic features of the tumor microenvironment, inhibit lymphocyte proliferation after cytokine stimulation (Loeffler et al., 1992) .
The effects of glutamate, however, are still controversial. It has been found in bronchial carcinoma patients that elevated glutamate levels in plasma were detrimental to the function of lymphocytes (Eck et al., 1989) , probably by interfering with their cystine membrane transport (Droge et al., 1992) . On the other hand, more recent reports show that dietary glutamate enhances immune response after chemotherapy by providing a stable source of glutamine to immune cells (Lin et al., 1999) .
The rise of anticancer therapeutics targeting metabolism
The Warburg effect in cancer cells has been successfully exploited in the clinic for some time now for diagnosis. Solid tumors with a sufficiently high glucose uptake can be imaged in patients using 18 Fluoro-deoxyglucose, which enters cells and is trapped inside them without further metabolism after phosphorylation, allowing its visualization by positron emission tomography (Pauwels et al., 2000) . A myriad of metabolic targets for potential anticancer drug candidates have also been already proposed (Kroemer and Pouyssegur, 2008; Tennant et al., 2010) , holding the promise to put cancer therapy several notches above its present status.
Until recently, antioxidants were thought to exert anticancer effects by scavenging ROS, preventing potentially genotoxic lesion (Cooke et al., 2003) . Indeed, experiments revealed well-established antioxidants to be potent suppressors of lymphoma growth in vivo by a decrease of HIF-1 levels rather than by genomic instability . Furthermore, it has also been reported that some acute myeloid leukemia patients have unusually high amounts of 2-hydroxyglutarate, as a result of a mutation either in the cytosolic or the mitochondrial isoform of isocitrate dehydrogenase. This metabolite inhibits HIF prolyl oxidase, and thus HIF hydroxylation and degradation. Strikingly, these patients did not present many of the chromosomal abnormalities often associated with that cancer, suggesting that this metabolic derangement modulates the malignant phenotype (Ward et al., 2010) .
From the clinical viewpoint, hypoxia in tumors is known for imparting radioresistance to cancer cells (Bertout et al., 2008) . Hypoxia targeting has proved rather elusive. Tirapazamine, is a prodrug that is solely reduced in hypoxic cells, provoking highly genotoxic DNA double-strand breaks. Its use before radiotherapy enhanced 3-year survival rates in phase-II trials (Rischin et al., 2005) , but it was found ineffectual in all considered parameters in a multinational phase-III trial (Rischin et al., 2010) . On the other hand, astounding results in human cancer patients have been achieved with small-molecule glycolysis inhibitors. A classical example is 5-thio-D-glucose: not only was it able to exquisitely kill hypoxic cells in spheroids in vitro (Song et al., 1978) , but it was also found later to protect healthy tissues in irradiated mice (Schuman et al., 1982) . Recently, other small molecules have been successfully tested. 3-Bromopyruvate, an analog of lactate that inhibits hexokinase, appeared effective in halting liver tumor growth when administered intra-arterially (Geschwind et al., 2002) . Also, dichloroacetate, which mimics pyruvate and inhibits PDKII, has been shown to reverse the Warburg effect, re-establishing pyruvate mitochondrial activation, enhance p53 activity and curb angiogenesis in tumor tissue derived from glioblastoma patients treated for 15 months (Michelakis et al., 2010) . Perhaps even more impressive, if confirmed, is the report of a patient with thyroid cancer that showed significant clinical improvement after daily treatment with citric acid (Halabe Bucay, 2009 ).
Mitochondrial bioenergetics is also becoming an attractive anticancer target. Many pharmacological agents able to specifically target these organelles in malignant cells without affecting their normal counterparts are being developed (Ralph et al., 2010) . The tumor suppression of mitochondrial respiration would decrease endogenous ROS generation, as inhibition of H þ -ATP synthase has been shown to delay ROSdependent cell death (Santamaria et al., 2006) . Downregulation of this (Shin et al., 2005) and other (Oliva et al., 2010) ETC complexes is indeed correlated with cancer chemoresistance. Finally, it must be mentioned that future directions of anticancer drug development may also include metabolic targets known to be involved in differentiation. For instance, ATP citrate lyase inhibitors lower cell growth and survival while inducing differentiation in tumors in vivo . These incipient approaches, if combined with conventional therapies, could diminish cancer recurrence after treatment of aggressive tumors.
To sum up, nodes of metabolic circuits can be exquisite targets for the design of a novel anticancer armamentarium showing high specificity and efficacy.
Perspectives
The tendency during the last decades has been to deal with cancer as solely driven by the gain of function of proto-oncogenes and loss of function of tumor-suppressor genes (Fearon and Vogelstein, 1990) . Although these concepts provided major insights into carcinogenesis, it is now clear that somatic factors cannot be ignored anymore, fueling the interest in cancer metabolism (Ferreira, 2010) . Cancer development is determined by Darwinian selective pressures. Those constitute the driving force for the appearance of successively more malignant cells whose subversion of the normal energy transduction and regulation pathways allows them to ultimately give rise to a tumor mass. When successful metastasis occurs, distant locations are colonized within the host, triggering a new life cycle of the cancer.
The Warburg effect was initially presented as the origin of cancer. Warburg averred that an irreversible injury to respiration had to occur in order to trigger the progressive striving of cells that had succeeded to engage in lactic fermentation to fulfill their energy needs, leading ultimately to the formation of a tumor (Warburg, 1956a) . Mutations in mitochondrial DNA (Bonora et al., 2006) , and defective mitochondrial lipid content and structure (Kiebish et al., 2008) , were found to squelch respiration in some tumors, while malfunction of some Krebs cycle enzymes also contributes to apoptosis resistance and aerobic glycolysis (King et al., 2006) . This suggests that mitochondrial defects may have a role in certain cancers. Yet, present knowledge indicates that Warburg effect might not be the prime cause of cancer. Mitochondrial defects in normal cells lead invariably to HIF-1a stabilization: while succinate dehydrogenase and fumarate hydratase dysfunction leads to prolyl hydroxylase inactivation by their substrates that leak into the cytosol (King et al., 2006) , ETC blockers enhance mitochondrial ROS production (Varum et al., 2009) , which have the same effect. HIF-1 activity alone retards normal cell proliferation (Koshiji et al., 2004) . It needs to be combined with MYC or perhaps other oncogenic protein over-activity in order to promote the cancer metabolic shift (Kim et al., 2007) and growth. MYC, in turn, does not induce apoptosis only when overexpressed in backgrounds where p53 function is compromised (Lowe et al., 2004) . p53 inactivation also allows AKT unchecked activity (Feng and Levine, 2010) , leading to cancerization and aerobic glycolysis (Staal, 1987; Elstrom et al., 2004) . Thus, the Warburg effect seems to arise from the concerted activity of various oncogenes during the carcinogenesis process and, in light of the present knowledge, may be better defined as the uncoupling between glycolysis and OXPHOS. However, even if it is not the cause, it is a necessary feature of most cancers. The universality of the Warburg effect has been disproved by cases such as Morris hepatomas, which are only modestly glycolytic (Weinhouse, 1972) ; tumors arising from adult mesenchymal stem cells, which show enhanced OXPHOS (Funes et al., 2007) ; and by the fact that knockdown of p32, which codes for a cell-surface receptor, upregulates lactic generation in detriment of OXPHOS and yet hampers tumorigenicity in breast cancer cells (Fogal et al., 2010) . Nonetheless, recent experiments have unequivocally shown that metabolic changes may precede tumor inception and recession . Hence, the metabolic changes occurring during carcinogenesis and, in particular, the Warburg effect, deserve to be included amongst the so-called 'hallmarks' of cancer (Hanahan and Weinberg, 2011) .
Interestingly, the deranged energy metabolism of tumors may not only actively participate in successive rounds of clonal selection for cells with genetic mutations with increasing malignant potential, but it can actually have a direct impact on gene expression by perturbing epigenetic regulation. Epigenetics concerns the heritable changes in phenotype that occur without affecting the DNA sequence itself, but rather involving DNA and histone chemical modifications (for example, methylations). This field is gaining momentum in cancer research as many cancers are associated with demethylation in oncogenes and/or over-methylation in tumor-suppressor genes, enhancing and repressing their transcription, respectively (Feinberg et al., 2006) . Choline, a methyl donor, could be an example of a relation between metabolism and epigenetics in cancer, as its deficiency was found to induce liver cancer (Newberne, 2002) . There are now several metabolites whose levels are known to quantitatively impact DNA and histone modifications, as they serve as substrates or precursors for such reactions (Luo and Kuo, 2009) . Could then bioenergetics leave a mark in cancer cells' genome such that the cancer metabolic pattern could be passed across cell generations owing to somatic factors, as proposed by Warburg (Warburg, 1930) ? Future research will certainly shed light on this exciting incipient field of cancer biology.
We have seen throughout this review that a metabolic approach to study the intricacies of tumorigenesis may well prove instrumental to further advance the knowledge on this disease. The field of cancer metabolism has come to stay and brings with it a promise to make side-effect-less medicine for cancer patients a reality in a near future.
